Screening for Chronic Kidney Disease
Authors: Ian H. de Boer
Journal: Annals of Internal Medicine (2013)

Letters5 March 2013Screening for Chronic Kidney DiseaseIan H. de Boer, MD, MS, Grant A. Olan, MA, and Uptal D. Patel, MD, on behalf of the American Society of Nephrology Chronic Kidney Disease Advisory GroupIan H. de Boer, MD, MSFrom Seattle, Washington; Washington, DC; and Durham, North Carolina., Grant A. Olan, MAFrom Seattle, Washington; Washington, DC; and Durham, North Carolina., and Uptal D. Patel, MDFrom Seattle, Washington; Washington, DC; and Durham, North Carolina., on behalf of the American Society of Nephrology Chronic Kidney Disease Advisory GroupAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-5-201303050-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Chronic kidney disease (CKD) is a serious and growing public health threat (1, 2). More than 26 million Americans are estimated to have CKD, and only 1 in 10 is aware that he or she has it. When identified early, however, the progression of CKD to end-stage renal disease can be slowed or halted (3). The American Society of Nephrology (ASN) CKD Advisory Group agrees with the U.S. Preventive Services Task Force (USPSTF) recommendation (4) that insufficient evidence exists to show that screening for CKD in asymptomatic adults translates into use of effective interventions that in turn ...References1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-47. [PMID: 17986697] CrossrefMedlineGoogle Scholar2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532-9. [PMID: 21693741] CrossrefMedlineGoogle Scholar3. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review no. 37. AHRQ publication no. 11(12)-EHC075-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Google Scholar4. Moyer VA; U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:567-70. [PMID: 22928170] LinkGoogle Scholar5. Crews DC, Plantinga LC, Miller ER, Saran R, Hedgeman E, Saydah SH, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension. 2010;55:1102-9. [PMID: 20308607] CrossrefMedlineGoogle Scholar6. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49:S12-154. [PMID: 17276798] CrossrefMedlineGoogle Scholar7. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35 Suppl 1 S11-63. [PMID: 22187469] CrossrefMedlineGoogle Scholar8. NICE Guideline Development Group. Chronic Kidney Disease: Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence; 2008. Accessed at www.nice.org.uk/cg73 on 6 December 2012. Google Scholar9. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al; American Heart Association Kidney and Cardiovascular Disease Council. Detection of chronic kidney disease in patients with or at increased risk for cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114:1083-7. [PMID: 16894032] MedlineGoogle Scholar10. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841-5. [PMID: 20647424] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Seattle, Washington; Washington, DC; and Durham, North Carolina.Disclosures: Dr. de Boer: Grants/grants pending (money to institution): Abbott Laboratories. Mr. Olan: None disclosed. Mr. Patel: Consultancy: Abbott Laboratories, Daiichi Sankyo, Kai Pharmaceuticals; Consultancy (money to institution): Amgen, Eli Lilly. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoScreening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement Virginia A. Moyer and Metrics Cited ByEvaluation of Systematic Blood Testing at the Time of Recruitment to the Armed Forces: Retrospective Monocentric Study Among 726 French Army SoldiersClinical Assessment and Management of Chronic Kidney Disease Across Its StagesUse of a Medical-Alert Accessory in CKDClinical Assessment and Management of Chronic Kidney Disease Across its StagesScreening for kidney disease—a lost opportunity 5 March 2013Volume 158, Issue 5_Part_1Page: 362-363KeywordsCardiovascular disease riskChronic kidney diseaseConflicts of interestDiabetes mellitusHypertensionMedical risk factorsNephrologyPopulation statisticsPrevention, policy, and public healthRenal failure ePublished: 5 March 2013 Issue Published: 5 March 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...